Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Quick View
Quisque mi est, blandit sed maximus
Original price was: $63.00.$57.00Current price is: $57.00.Add to cartDuis feugiat sapien et augue dignissim porta. Nullam magna velit, laoreet porta vestibulum nec, auctor sed dui. Integer ac sodales enim. Quisque magna est, mollis euismod nibh in, elementum congue orci. Cras viverra, elit vitae iaculis efficitur, turpis urna sodales eros, vel finibus lacus elit sit amet dolor. Praesent at erat in purus pretium laoreet.
-
Quick View
Nunc tempus facilisis
$87.00Add to cartFusce ullamcorper dapibus eleifend. Nullam ornare pulvinar lacinia. Nunc tempus facilisis ullamcorper. Nam sit amet suscipit risus, ut ultricies felis. Vivamus a finibus nisi. Sed quam sem, accumsan eget tristique sit amet, suscipit sit amet augue. Duis dolor dui, sagittis at faucibus ac, varius et sapien.
-
Quick View
Morbi varius ligula eget ante
Original price was: $55.00.$45.00Current price is: $45.00.Add to cartMaecenas nulla est, dictum quis augue ultrices, dictum rutrum enim. Aliquam erat volutpat. Quisque ultricies ornare lacus, eu sagittis urna euismod ac. Nulla rhoncus ultrices ligula, id maximus ligula ultricies non.
-
Quick View
Pellentesque dignissim sapien semper
$78.00Add to cartCras luctus ultricies ex luctus malesuada. Fusce imperdiet interdum consectetur. Pellentesque dignissim sapien semper consequat sollicitudin. Phasellus iaculis libero ac placerat aliquam. Etiam a velit eu diam consequat vestibulum. Ut a malesuada nulla. Vivamus quis maximus nisi, vel molestie sapien. Nunc pharetra finibus elit sed consectetur.
Reviews
There are no reviews yet.